https://scholars.lib.ntu.edu.tw/handle/123456789/512431| Title: | Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior? | Authors: | Chang C.-H. Lee C.-H. JANN-YUAN WANG |
Issue Date: | 2017 | Publisher: | American Society of Clinical Oncology | Journal Volume: | 35 | Journal Issue: | 12 | Start page/Pages: | 1374 | Source: | Journal of Clinical Oncology | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017648983&doi=10.1200%2fJCO.2016.68.5842&partnerID=40&md5=bf416f9851f31ac9954cdbdd3e8343a5 https://scholars.lib.ntu.edu.tw/handle/123456789/512431 |
ISSN: | 0732-183X | DOI: | 10.1200/JCO.2016.68.5842 | SDG/Keyword: | [SDGs]SDG3 epidermal growth factor receptor; erlotinib; gefitinib; erlotinib; gefitinib; quinazoline derivative; cancer chemotherapy; cancer patient; cancer recurrence; cancer staging; cancer survival; comparative effectiveness; drug efficacy; gene mutation; human; Letter; lung adenocarcinoma; maximum tolerated dose; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); treatment duration; lung adenocarcinoma; lung tumor; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.